Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Veramark Technologies, Inc. (NASDAQ: VERA) | Delayed: 29.05 -2.15 (6.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.20 | 52 Week High | $1.18 | |||
| Open | $30.99 | 52 Week Low | $0.36 | |||
| Day High | $31.84 | P/E | 484.17 | |||
| Day Low | $28.71 | EPS | $0.06 | |||
| Volume | 2,545,669 | |||||
